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Abstract
Background: The heterogeneous nature of acute myeloid leukemia (AML) and the hurdle to find a suitable treatment strategy for
this malignancy put this type of leukemia at the top of the list of the priorities for finding a valuable biomarker to improve its
treatment and predict the outcome of the patients.
Objectives: Given the involvement of the variety of signaling pathways, foremost the PI3K axis in the pathogenesis of human can-
cers, we aimed to investigate the expression of the most important downstream targets of this pathway to propose a plausible
mechanism underlying AML pathogenesis.
Methods: In this case-control study, the blood samples from 30 patients diagnosed with AML were collected and after extracting
their RNAs, the expression levels of Akt, c-Myc, CIP2A, and PP2A were evaluated using qRT-PCR analysis. For the control group, we
also collected blood samples from 10 healthy volunteers. Afterward, by applying statistical analysis, we determined the probable
correlation between the expressions of the aforementioned genes.
Results: There was a significant elevation in the expression levels of Akt, c-Myc, and CIP2A coupled with the meaningful reduction
in the expression level of PP2A in AML samples. However, we failed to find any significant association between the expression level
of the indicated genes and age, sex, and the percentage of the blasts.
Conclusions: As the most straightforward interpretation of our results, we propose that probably the association between PI3K
and c-Myc which is built through the interaction between CIP2A and PP2A may play a pivotal role in the pathogenies of AML and any
component of this axis could serve as a potential new target for more profound treatment strategy. However, further detailed inves-
tigations in this field are required to clarify the exact role of this interesting testis-specific pathway in the context of hematological
malignancies, in particular AML.
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1. Background
By the advent of targeted therapies and its initial suc-
cess in inducing a profound impact on cancer patients out-
come, a new gate of hope has been opened for patients to
overcome the disease; nonetheless, significant challenges
are still remained to maximize the clinical benefit of tar-
geted therapy (1). Ever-increasing attempts have been done
thus far to identify more novel biomarkers not only to
predict the prognosis but also to target it through thera-
peutic interventions (2). Among different types of human
cancers, leukemia, in particular acute myeloid leukemia
(AML), is notorious for its heterogeneous genetic features
as multiple molecules and signaling pathways play funda-
mental roles in the molecular pathogenesis of this malig-
nancy (3). Moreover, despite the promising improvements
in the treatment strategies and significant increase in 5-
year event-free survivals (EFS), still the early incidence of re-
lapse in AML, which is widely associated with the aberrant
expression of mounting body of genes, is a frequent event
(4). Notably, this unique characteristic put AML at the fore-
Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly
cited.
Uncorrected Proof
Sayyadi M et al.
front of the priority to be fully studied for the identifica-
tion of novel biomarkers that are involved in the primary
stages of leukemogenesis (5).
In the pathogenesis of AML, deregulation of several
signaling pathways has been reported to participate in
the maintenance of hematopoietic progenitor cells sur-
vival. Since PI3K signaling axis is located at the upstream of
survival pathways and oncogenic mediators, several stud-
ies have reported that the inhibition of this axis, either
as a single treatment or in combination with chemother-
apy, could be a valuable strategy to eliminate the survival
of leukemic cells (6-10). However, although this inhibi-
tion was quite effective, the precise role of the PI3K net-
work in the pathogenesis of AML is still a debatable is-
sue. Although there are some reports suggesting that the
activation of PI3K could participate in the early stage of
AML formation, others claimed that the aberrancy in this
pathway is acquired after the application of chemothera-
peutic drugs (11). Apart from direct impact on the evolu-
tion of myeloid leukemia cells, the regulatory role of the
PI3K pathway on the expression of c-Myc as an oncogene
with a well-established influence on the transformation
of myeloid progenitors has resulted in re-consideration of
PI3K role in the pathogenesis of AML (12). The discrepan-
cies on the pathogenic value of PI3K and its downstream
targets in AML patients on one hand, and the importance
of the proposing a plausible mechanism underlying AML
pathogenesis on the other hand, encouraged us not only
to evaluate the expression levels of the main component
of the PI3K pathway including Akt, c-Myc, CIP2A, and PP2A
in newly diagnosed AML patients but also to investigate if
there is any correlation between aforementioned genes in
this leukemia.
2. Objectives
Given the involvement of the variety of signaling path-
ways foremost the PI3K axis in the pathogenesis of hu-
man cancers, we aimed at investigating the expression of
the most important downstream targets of this pathway
to propose a plausible mechanism underlying AML patho-
genesis.
3. Methods
3.1. Patients Sample Collection
From October 2018 to August 2019, peripheral blood
samples obtained from 30 de-novo AML patients and
10 healthy controls. The research protocol was ap-
proved by the Research Ethics Committee at the Shahid
Beheshti University of Medical Sciences (ID number:
IR.SBMU.RETECH.REC.1397.1012) and all participants signed
informed consent document in accordance with the state-
ment of Helsinki. The clinical characteristics of partici-
pants with de novo AML are illustrated in Table 1. Patients
were diagnosed according to French-American-British
(FAB) classification, which categorizes AML subtypes based
on morphologic characteristics of malignant cells. Among
all collected samples, 86.5% were diagnosed as non-M3
AML and 13.5% were categorised as AML-M3. The mean age
of the patients at the time of diagnosis was ~ 56 years.
Noteworthy, 56% of the samples (16 out of 30) were col-
lected from male and 44% of the samples (14 out of 30)
were allocated to female patients.
3.2. RNA Purification and Preparation of cDNA
Total cellular RNA from mononuclear cells (MNCs) of
participants was extracted using High Pure RNA isolation
kit (Qiagen, Germany) as recommended by the supplier.
The amount of extracted RNA was spectrophotometrically
assessed using Nanodrop ND-1000 (Optical Density (OD)
260/280 nm ratio > 1.8). Subsequently, 1µg RNA was used to
synthesize cDNA in a final volume of 20µL using a Thermo
fermentas kit according to the manufacturer’s protocol
(Thermo scientific - USA).
3.3. Real-Time Quantitative PCR
To evaluate the expression levels of genes, sense and an-
tisense primers of target genes were designed by GeneRun-
ner software (details are shown in Table 2). Alterations in
the mRNA expression levels of genes were measured using
SYBR green-based real-time quantitative polymerase chain
reaction (qRT-PCR) (Rotor-Gene 6000, Qiagen, Germany). A
15 µL reaction containing 2 µL cDNA, 1 µL Sense and anti-
sense primers, 7.5 µL of master Mix (Ampliqon, Denmark),
as well as 4.5 µL water was amplified in thermal cycler. For
each target gene, primer efficiency was estimated from a
standard curve using four consecutive 1:10 dilutions of the
cDNA sample. ABL was amplified as housekeeping genes.
All tests were done in triplicate and fold changes in the ex-
pressions of each mRNA were calculated using the Livak
method (2-∆∆CT) (13).
3.4. Statistical Analysis
All the statistical analyses were performed using the
SPSS software (version 16.0) and the GraphPad Prism 6 soft-
ware. Independent student t or Mann-Whitney U tests were
conducted for comparison between patients and the con-
trol group. Pearson’s correlation test was used to study the
possible correlation between the indicated genes. A prob-
ability value of less than 0.05 was considered statistically
significant.
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Table 1. The Clinical Characteristics of De Novo Acute Myeloid Leukemia Patients
No. FAB RBC× 106 WBC× 103 Hb (g/dL) Hct (%) Plt× 103 Blast (%)
1 AML-M2 3.32 24.7 9.7 28.4 48 35
2 AML-M1 2.79 50.01 9.2 27.9 165 50
3 AML-M2 3.12 86.45 9.5 28.1 78 65
4 AML-M2 4.41 32.14 12.9 38.7 170 40
5 AML-M0 2.98 45.24 10.1 28.8 93 35
6 AML-M4 2.71 23.39 8.7 26.1 238 25
7 AML-M2 3.58 14.46 10.5 29.3 24 60
8 AML-M5 3.5 37.06 9.8 31.6 55 25
9 AML-M3 2.95 75.54 9.2 25.7 53 45
10 AML-M4 3.53 11.11 10.6 31.3 80 80
11 AML-M2 5.34 15.34 14.6 42.1 160 45
12 AML-M3 5.19 56.61 15.8 46.0 137 55
13 AML-M1 2.31 108 6.01 21.0 10 40
14 AML-M2 4.1 36.45 11.39 34.0 78 80
15 AML-M4 5.01 13 14.6 42.14 175 80
16 AML-M5 3.03 36.54 9.5 27.3 45 90
17 AML-M3 2.42 99.14 8.3 24.8 141 43
18 AML-M4 4.18 16.36 12.3 38.05 189 26
19 AML-M6 4.45 17.45 13.5 40.4 173 32
20 AML-M2 3.56 54.04 11.6 34.4 121 41
21 AML-M1 3.06 14.4 9.3 26.6 63 21
22 AML-M2 2.75 29.5 10.3 31.4 69 38
23 AML-M4 3.43 27.76 9.5 31.3 91 41
24 AML-M2 3.37 106.7 9.4 29.2 35 68
25 AML-M3 3.11 19.45 9.3 27.7 116 51
26 AML-M2 3.33 16.86 10.3 30.2 31 65
27 AML-M4 4.17 18.54 9.8 28.1 26 35
28 AML-M5 3.67 21.41 8.6 26.1 32 40
29 AML-M2 4.02 13.52 11.7 34 15 30
30 AML-M1 2.89 42.51 9.9 29.41 62 28
Abbreviations: Hb, hemoglobin; RBC, red blood cells; WBC, white blood cells.
Table 2. Nucleotide Sequences of the Primers Used for Real-Time RT-PCR
Gene Accession Number Forward Primer (5’-3’) Reverse Primer (5’-3’) Size
ABL NM-005157 TCCTCGTCCTCCAGCTGTTA ACCCGGAGCTTTTCACCTTT 218
Akt NM-005163 TCCTCCTCAAGAATGATGGCA GTGCGTTCGATGACAGTGGT 181
c-Myc NM-002467 CCACAGCAAACCTCCTCACAG GCAGGATAGTCCTTCCGAGTG 105
CIP2A NM-020890 ACCCCAACATAAGTGCTTCAC TCTCTGGTTTCAATGTCTACTGC 79
PP2A NM-178001 TCTCAGGCATACGCTGACTAC GGAGACTCTGTACTCGAAGGT 90
4. Results
4.1. The Expression Level of CIP2A and PP2A in AML Samples
The prognostic value for CIP2A, a direct inhibitor of a
tumour suppressor PP2A, has been reported in wide range
of human solid tumours (14); however, its association with
human leukaemia has not yet been clarified. To assess the
expression level of CIP2A and its downstream target PP2A
in AML and also to explore its plausible contributory role in
leukomogensis, peripheral blood of 30 AML patients (56%
male and 44% female) with the median age of 49 years old
were collected for quantitative real-time PCR analysis. In
addition, 10 normal cases were also included as a control
group in order to provide a better outlook for the alter-
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ation in the gene expression pattern. We found that the in-
creased expression of CIP2A in AML samples was coupled
with the reduction in mRNA level of its downstream target
PP2A (Figure 1A). Based on the results, the expression level
of both CIP2A and PP2A was different in AML patients and
healthy individuals, it was of particular interest to evaluate
whether the alteration in the expression pattern of these
genes has any association with age, gender, and the per-
centage of blasts. As presented in Table 3, we found the
similar expression pattern both in male and female groups
and also in all age categories that we have divided our sam-
ples into. The same result has been also obtained when we
compared the mRNA level of these genes with the percent-
age of the blasts (Table 3).
4.2. The Expression Level of Akt and c-Myc Was Increased in AML
Patients as Compared to Healthy Counterparts
Previous studies have shown that there is a cross-talk
between PP2A downregulation and c-Myc expression in
malignant cells (15). It has been reported that not only
c-Myc could suppress the expression of PP2A and thereby
prolong the survival signals in the neoplastic cells, but also
the decrease in the expression level of PP2A is associated
with stabilizing phosphorylated c-Myc in malignant cells
(16). Given this and based on our results, we also aimed
to examine the expression level of c-Myc in AML patients.
The results of the qRT-PCR analysis revealed that the ex-
pression level of this oncogene was significantly higher as
compared with the healthy counterparts (Figure 1B); sug-
gestive of the oncogenic role of c-Myc in the leukemogen-
esis process. It has been reported that c-Myc, located at the
downstream of the PI3K/Akt signaling pathway, serves as
a mediator to transmit the survival signals to the nucleus
and thereby orchestrate the variety of cellular functions
(17). Accordingly, the results of qRT-PCR analysis indicated
that the expression level of the Akt has been elevated in the
AML samples as compared to its expression in the healthy
individuals (Figure 1B). By applying the Livak method, we
also found that there was not a significant correlation be-
tween the mRNA expression patterns of these genes with
age, gender, and the percentage of blasts (Table 4).
4.3. Correlation Between Akt, c-Myc, CIP2A, and PP2A Expression
Levels in the Studied Groups
Having established that there was a significant differ-
ence between the expression levels of the indicated genes
among AML patients and healthy counterparts, we then
used statistical correlation analysis to evaluate whether
there is a significant correlation between the expression
levels of the genes in the patients group. Our results
showed that a significant correlation exists between gene
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Figure 1. A, while the expression levels of CIP2A in leukemic patients were signif-
icantly higher than the control group, the mRNA expression level of PPI2A signifi-
cantly decreased; B, there was a significant elevation in the expression levels of both
Akt and c-Myc in leukemia patients as compared with samples collected from the
normal volunteers. Values are given as mean± standard deviation of three inde-
pendent experiments.
expression levels of PP2A and CIP2A (r = -0.49, P < 0.01), Akt
and c-Myc (r = 0.57, P < 0.05), c-Myc and PP2A (r = -0.54, P
< 0.01), Akt and PP2A (r = -0.65, P < 0.01), c-Myc and CIP2A
(r = 0.48, P < 0.05), and Akt and CIP2A (r = 0.67, P < 0.05)
(Figure 2); showing the prominent role of this axis in the
pathogenesis of AML.
5. Discussion
Despite dramatic therapeutic advances in recent years,
the minimal overall survival (OS) for AML patients ascer-
tained the importance of the identification of the new
biomarkers to provide a better outlook of the disease
pathogenesis (18). When the results of genetic and molec-
ular experiments showed that the aberrancy in the expres-
sion or activity of c-Myc oncogene is a frequent occurrence
in AML patients, intense interest has been attracted to this
factor to evaluate its association with either pathogenesis
or prognosis of the disease. The results of the mutation
analysis in AML patients showed that in contrast to several
malignant hematopoietic cells such as multiple myeloma
(MM) and non-Hodgkin lymphoma (NHL), which in them
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Evaluable Patients Evaluable Patients
CIP2A (↑) CIP2A (↓) P Value PP2A (↑) PP2A (↓) P Value
Age, y 49, 19 - 83 0.325 0.871
n < 60 19 (63.3) 14 (46.6) 5 (17) 7 (23.3) 12 (40)
n≥ 60 11 (36.4) 8 (26.4) 3 (10) 3 (10) 8 (26.7)
Sex 0.470 0.312
Male 17 (56) 10 (33.3) 7 (23.4) 4 (13.3) 13 (43.3)
Female 13 (44) 9 (30) 4 (13.3) 3 (10) 10 (33.4)
Percentage of blast 0.556 0.117
n < 40 10 (33.3) 9 (30) 1 (3) 2 (6) 8 (26.7)
n≥ 40 20 (66.7) 13 (43.3) 7 (23.7) 4 (13.3) 16 (54)
AML subtype 0.281 0.120
M3 4 (13.5) 2 (6.5) 2 (6.5) 1 (3) 3 (10)
Non-M3 26 (86.5) 20 (67) 6 (20) 5 (16.4) 21 (70.6)
Abbreviation: AML, acute myeloid leukemia.
aValues are expressed as No. (%) or median, range.
bStatistically significant values: P < 0.05.




Evaluable Patients Evaluable Patients
Akt (↑) Akt (↓) P Value c-Myc (↑) c-Myc (↓) P Value
Age, y 49, 19 - 83 0.254
n < 60 19 (63.3) 13 (43) 6 (20) 0.435 15 (50) 4 (13.3)
n≥ 60 11 (36.4) 9 (30) 2 (15) 7 (23.4) 4 (13.3)
Sex 0.120
Male 17 (56) 12 (40) 5 (16.6) 0.740 11 (36.6) 6 (20)
Female 13 (44) 10 (33.3) 3 (10) 10 (33.3) 3 (10)
Percentage of blast 0.391
n < 40 10 (33.3) 7 (23.3) 3 (10) 0.276 8 (26.3) 2 (6)
n≥ 40 20 (66.7) 15 (50) 5 (16.7) 16 (53.3) 4 (13.4)
AML subtype 0.726
M3 4 (13.5) 3 (10) 1 (3) 0.178 3 (10) 1 (3)
Non-M3 26 (86.5) 22 (73.3) 4 (13.7) 20 (67) 6 (20)
Abbreviation: AML, acute myeloid leukemia.
aValues are expressed as No. (%) or median, range.
bStatistically significant values: P < 0.05.
c-Myc serves both as prognostic and pathogenic mediators
(19, 20), mutations in c-Myc gene may not play a pivotal role
in the initiation of AML (21). However, Xia et al. revealed
that c-Myc may serve as a resistance biomarker in AML pa-
tients (22). In the present study, we found that the expres-
sion level of c-Myc was elevated in AML samples; however,
we could find no significant correlation between its expres-
sion and the difference in age, gender, and the percentage
of the blasts. In agreement, accumulating evidence also in-
dicated that the high expression level of c-Myc in the neo-
plastic myeloid cells could be an important criterion for
the development of the disease and the induction of drug-
resistance in AML patients (23, 24). Notably, the results of
other investigations showed that by inhibition of c-Myc
in acute leukemia cells, not only the survival of the cells
were significantly reduced (25, 26), but also this suppres-
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Figure 2. Correlation between the expression level of Akt, c-Myc, CIP2A, and PP2A in leukemic samples. Normal distribution of data was achieved by log 10 computation and
correlation between Akt, c-Myc, CIP2A, and PP2A was determined in 30 AML patients. Values are given as mean± standard deviation of three independent experiments.
sion resulted in the enhancement of the therapeutic value
of chemotherapeutic drugs (26, 27), which demonstrates
the contributory role of c-Myc in the pathogenesis of AML.
Multiple mediators have been demonstrated to be in-
volved in the regulation of c-Myc in malignant cells, which
amongst them the PI3K signaling pathway has been recog-
nized as one of the most important axis to harness the ac-
tivity of this oncogene (28). Apart from c-Myc regulation,
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Figure 3. Schematic representation proposed for the plausible role of PI3K axis in AML cells. Through aberrant activation of the PI3K signaling pathway which subsequently
leads to the over-expression of Akt, c-Myc would be expressed in malignant cells and turn lead to the excessive expression of CIP2A, a direct inhibitor of PP2A. Upon PP2A
suppression, Akt and c-Myc remained phosphorylated and this defective loop may be responsible for providing an opportunity for AML cells to proliferate more vigorously.
given the harmonizing role of the PI3K axis in the wide
range of intracellular functions, the oncogenic role of this
network has always been under the magnifying glass. Anal-
ysis of the crucial role of the PI3K aberrancy and more pre-
cisely the over-expression of Akt, as the main downstream
component of the PI3K axis, in chronic lymphoid leukemia
(CLL) recently led to the application of the PI3K inhibitors
in the therapeutic approaches of this malignancy (29),
which in turn resulted in an increased tendency to study
the role of this axis in the other types of hematologic malig-
nancies. Some studies suggested that in different types of
AML, AML-M3 (APL) which is notorious for the translocation
of PML-RARα displays a greater amount of over-activated
Akt (30, 31). Accordingly, other studies indicated that the
cell lines of AML-M3 are more sensitive to the antileukemic
effect of PI3K inhibitors as compared to other AML-derived
cell lines (32). However, in the present study, we found
that in AML patients either diagnosed as M3 or non-M3, the
expression level of Akt was greater than healthy counter-
parts, which was in agreement with the elevated c-Myc in
these patients; further highlighting the fact that the acti-
vation of the PI3K/Akt/c-Myc axis may be a plausible event
participating in AML pathogenesis.
Genomic and proteomic approaches have widely de-
clared that the sync between PI3K and c-Myc would not
be accomplished unless PP2A phosphatase would be inhib-
ited by its dominant inhibitor CIP2A (cell proliferation reg-
ulating inhibitor of PP2A) (33). In another word, whether
through PI3K or c-Myc, CIP2A would be activated and sub-
sequently by the suppression of PP2A this oncogene would
construct a defective loop through which both Akt and c-
Myc would be stabilized, giving the malignant cells an op-
portunity to proliferate more vigorously (33, 34). In agree-
ment, our results delineated that in AML patients with an
over-expressed profile of both c-Myc and Akt, there was an
elevation in the expression level of CIP2A. Interestingly, we
also found that the mRNA level of PP2A was decreased in
AML patients as compared to the control group. The role of
PP2A in AML pathogenesis has not yet been well-clarified,
and this study for the first time suggested that probably
this gene serves as a missing point through which PI3K/c-
Myc axis could regulate the expression level of CIP2A (Fig-
ure 3).
5.1. Conclusions
Taken together and as the most straightforward inter-
pretation of our results, we proposed that probably the as-
sociation between PI3K and c-Myc which is built through
the interaction between CIP2A and PP2A may play a pivotal
role in the pathogenies of AML and any component of this
axis could serve as a potential new target to interfere in the
novel treatment strategies. However, further detailed in-
vestigations in this field are required to clarify the exact
role of this interesting testis-specific pathway in the con-
text of hematological malignancies, in particular AML.
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